{"changeSha256":"1d756c6eec87f3cf5d7f6b271e9b9a33492ea62e318bafdf98ca90eaf4af13e2","changedAt":"2026-11-14","changedFields":[{"after":"FDA-approved as Langlara","before":"U.S. label record","field":"Status"},{"after":"A long-acting insulin glargine product licensed by FDA as Langlara in April 2026 to improve blood-sugar control in adults and children with diabetes.","before":"A long-acting insulin analogue. This profile cites a U.S. prescription label.","field":"Profile summary"},{"after":"FDA’s approval letter describes the application as seeking licensure as biosimilar to and interchangeable with US-licensed Lantus. The clinical studies in the label are insulin glargine studies against NPH insulin, not trials of insulin glargine-aldy itself.","before":"The cited DailyMed label identifies Insulin glargine-aldy and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.","field":"Evidence note"},{"after":"dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026","before":"dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5","field":"Cited source records"},{"after":"U.S. National Library of Medicine [sources: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5]; U.S. Food and Drug Administration [sources: fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026]","before":"U.S. National Library of Medicine [sources: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5]","field":"Named organizations"},{"after":"name: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; aliases: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; category: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; status: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; summary: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026; evidenceNote: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5, fda-langlara-approval-2026","before":"name: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; aliases: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; category: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; status: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; summary: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5; evidenceNote: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/insulin-glargine-aldy/versions/3/","version":3},"id":"profile:insulin-glargine-aldy:v3","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, re-checked the Langlara label, and added the Drugs@FDA record and FDA’s April 2026 approval letter.","peptideSlugs":["insulin-glargine-aldy"],"previousChangeEvent":{"path":"/corrections/v1/profiles/insulin-glargine-aldy/v2.json","sha256":"73a93d435cbaf04e1a65609a76f20a985b3748a5fc7c4dd63d5ae76503e2f049"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/insulin-glargine-aldy/versions/2/","version":2},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5","name":"DailyMed · U.S. National Library of Medicine","sourceClass":"A","title":"LANGLARA (insulin glargine-aldy) injection, solution · SPL version 5 · published 2026-07-08","url":"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=5328761e-59d3-ca7a-e063-6394a90ae810&version=5","verifiedAt":"2026-07-22"},{"id":"fda-drugs-bla761412-2026-04-29-d6855121c0c6","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application BLA761412 · original submission status AP · 2026-04-29 · dataset 2026-08-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22BLA761412%22&limit=1","verifiedAt":"2026-08-14"},{"id":"fda-langlara-approval-2026","name":"U.S. Food and Drug Administration","sourceClass":"A","title":"Langlara (insulin glargine-aldy): BLA 761412 approval letter, April 29, 2026","url":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761412Orig1s000ltr.pdf","verifiedAt":"2026-11-14"}],"subject":{"slug":"insulin-glargine-aldy","type":"profile"}}
